Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

Delayed Quote. Delayed  - 07/22 10:00:00 pm
65.49 USD   +0.80%
07/12 ALNYLAM PHARMAC : to Host Third Annual "RNAi Roundtable" Webcast Ser..
07/07 ALNYLAM PHARMAC : Initiates Phase 1/2 Clinical Trial for ALN-HBV, an..
07/01 ALNYLAM PHARMAC : Reports New Results from Investigational RNAi Ther..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/18/2016 07/19/2016 07/20/2016 07/21/2016 07/22/2016 Date
64.83(c) 64.03(c) 65.74(c) 64.97(c) 65.49(c) Last
661 777 906 201 666 890 774 176 763 204 Volume
+0.54% -1.23% +2.67% -1.17% +0.80% Change
More quotes
Financials ($)
Sales 2016 41,7 M
EBIT 2016 -436 M
Net income 2016 -421 M
Finance 2016 583 M
Yield 2016 -
Sales 2017 58,0 M
EBIT 2017 -478 M
Net income 2017 -464 M
Finance 2017 455 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 120x
EV / Sales2017 88,6x
Capitalization 5 590 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
07/12 ALNYLAM PHARMACEUTICALS : to Host Third Annual "RNAi Roundtable" Webcast Series
07/07 ALNYLAM PHARMACEUTICALS : Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Inv..
07/01 ALNYLAM PHARMACEUTICALS : Reports New Results from Investigational RNAi Therapeu..
06/27 ALNYLAM PHARMACEUTICALS : to Report New Patisiran and Revusiran Results at the X..
06/23 ALNYLAM PHARMACEUTICALS : Supports Greater Boston and Norton Communities with it..
06/23 ALNYLAM PHARMACEUTICALS : Supports Greater Boston and Norton Communities with it..
06/17 ALNYLAM PHARMACEUTICALS : Biotechnology Equities Technical Review -- Geron, Merr..
06/16 ALNYLAM PHARMACEUTICALS : Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an I..
06/15 ALNYLAM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
06/11 ALNYLAM PHARMACEUTICALS : Reports Initial ALN-CC5 Results in Patients with Parox..
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/21 Why Vision Matters
07/11 After Hours Gainers / Losers
07/08 Genmab And Tesaro Lead First-Half Gainers As Endo And Infinity Falter
06/27 Cigna's Merger Is DOA - Cramer's Lightning Round (6/24/16)
06/23 Amyloidosis Pipeline Still Looks To Alnylam For Answers
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 117 $
Spread / Average Target 78%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President & Chief Operating Officer
Michael W. Bonney Chairman
David-Alexandre Gros Chief Financial Officer
Akshay K. Vaishnaw Chief Medical Officer, EVP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..-30.43%5 590
INCYTE CORPORATION-20.32%16 212
CELLTRION, INC.--.--%10 689
LONZA GROUP AG11.40%9 737
QUINTILES TRANSNATIONA..7.82%8 859
ALKERMES PLC-37.26%7 528
More Results